CNS Drugs

, Volume 17, Issue 15, pp 1119–1122 | Cite as

Treatment of Recurrent Depression

An Alternate Viewpoint
  • Michael E. Thase

Depression is one of the world’s greatest public health problems and, because most people who suffer from depression will experience multiple episodes of illness during their lifetimes, improving longer-term treatment options can be expected to greatly offset the staggering personal and societal costs of this common affliction. In the accompanying review article,[1] Professor Giovanni Fava and colleagues discuss the state of the evidence pertaining to preventive treatments for recurrent depressive disorders. Despite documenting progress in the field over the past decade, they raise a number of important concerns. In this commentary, I will focus on four of these issues:

  1. 1.

    Does tolerance develop to the effects of antidepressants during prophylaxis?

  2. 2.

    Are there evidence-based alternatives to maintenance pharmacotherapy?

  3. 3.

    Why is the role of psychosocial interventions under-valued for prophylaxis?

  4. 4.

    Should we tell our patients about the possible need for lifelong treatment?




  1. 1.
    Fava GA, Ruini C, Sonino N. Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach. CNS Drugs 2003; 17(15): 1109–1117PubMedCrossRefGoogle Scholar
  2. 2.
    Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653–61PubMedCrossRefGoogle Scholar
  3. 3.
    Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093–9PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart JW, Tricamo E, McGrath PJ, et al. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months’ remission. Am J Psychiatry 1997; 154: 31–6PubMedGoogle Scholar
  5. 5.
    Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280(19): 1665–72PubMedCrossRefGoogle Scholar
  6. 6.
    Thase ME, Nierenberg AA, Keller MB, et al., and the Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001; 62: 782–8PubMedCrossRefGoogle Scholar
  7. 7.
    Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002; 51: 753–61PubMedCrossRefGoogle Scholar
  8. 8.
    Gelenberg AJ, Arnow B, Borian FE, et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry 2003; 54: 806–17PubMedCrossRefGoogle Scholar
  9. 9.
    Kirsch I. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevent Treat 2002; 5: 1–12Google Scholar
  10. 10.
    Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevent Treat 1998; 1: 1–15Google Scholar
  11. 11.
    Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57: 311–7PubMedCrossRefGoogle Scholar
  12. 12.
    Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996; 11: 137–45PubMedGoogle Scholar
  13. 13.
    Montgomery SA, Roberts A, Patel AG. Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharm 1994; 9Suppl. 1: 49–53CrossRefGoogle Scholar
  14. 14.
    Montgomery SA, Reimitz P-E, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacology 1998; 13: 63–73CrossRefGoogle Scholar
  15. 15.
    Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up: findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992; 49: 782–7PubMedCrossRefGoogle Scholar
  16. 16.
    Reynolds III CF, Perel JM, Frank E, et al. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 1999; 156: 1177–81PubMedGoogle Scholar
  17. 17.
    Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295–9PubMedGoogle Scholar
  18. 18.
    Paykel ES, Scott J, Teasdaleet JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56: 829–35PubMedCrossRefGoogle Scholar
  19. 19.
    Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998; 55: 816–20PubMedCrossRefGoogle Scholar
  20. 20.
    Persons JB, Thase ME, Crits-Christoph P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry 1996; 53: 283–90PubMedCrossRefGoogle Scholar
  21. 21.
    American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993; 150Suppl. 4: 1–26Google Scholar
  22. 22.
    Parloff MB. Psychotherapy research evidence and reimbursement decisions: Bambi meets Godzilla. Am J Psychiatry 1982; 139: 718–27PubMedGoogle Scholar
  23. 23.
    Luborsky L, Diguer L, Seligman DA, et al. The researcher’s own therapy allegiances: a ‘wild card’ in comparisons of treatment efficacy. Clin Psychol Sci Pract 1999; 6: 95–106CrossRefGoogle Scholar
  24. 24.
    Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 1995; 63: 966–80PubMedCrossRefGoogle Scholar
  25. 25.
    Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.University of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations